|
US2021122764A1
|
|
Small Molecule Inhibitors of KRAS G12C Mutant
|
|
WO2021080929A1
|
|
N-(heteroaryl) quinazolin-2-amine derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
|
|
WO2021067229A2
|
|
Biomarkers for anti-tigit antibody treatment
|
|
WO2021067207A1
|
|
Apparatus and method for monitoring and recording disintegration times for pharmaceutical products
|
|
WO2021061719A1
|
|
Methods for treating metastatic triple negative breast cancer with anti-pd-1 antibodies
|
|
WO2021061594A1
|
|
Method for measuring nucleic acid content in lipid nanoprticles using ultraviolet spectrometry
|
|
WO2021055728A1
|
|
Small molecule inhibitors of kras g12c mutant
|
|
WO2021061504A1
|
|
Methods and compositions comprising an anti-ctla4 monoclonal antibody with reduced host cell proteins and increased polysorbate-80 stability
|
|
WO2021041770A1
|
|
Pcsk9 antagonist compounds
|
|
WO2021030306A1
|
|
Drug delivery system for the delivery of antiviral agents
|
|
WO2021026047A1
|
|
Heteroaryl pyrrolidine and piperidine orexin receptor agonists
|
|
WO2021021767A1
|
|
Anti-pd-1/lag3/tigit trispecific antibodies and anti-pd-1/lag3 bispecific antibodies
|
|
WO2021021567A1
|
|
Methods and assemblies for preparing and dispensing lyospheres of pharmaceutical compositions
|
|
WO2021021535A1
|
|
Glucose-responsive insulin conjugates
|
|
WO2021015987A1
|
|
Antigenic glycoprotein e polypeptides, compositions, and methods of use thereof
|
|
WO2020263717A1
|
|
Process for separating antigen-binding polypeptide monomers comprising one or more immunoglobulin single variable domains from aggregates
|
|
WO2020263660A1
|
|
Process for the preparation of 2-fluoroadenine
|
|
WO2020257153A1
|
|
P53 activator peptidomimetic macrocycles
|
|
WO2020257102A1
|
|
Containment system for mixing dry powders with solvents during drug production or processing
|
|
US2020401628A1
|
|
Radial map data visualization
|
